The estimated Net Worth of Justin J. Mc Anear is at least $4.63 Million dollars as of 22 August 2024. Mr. Anear owns over 2,961 units of 10x Genomics stock worth over $3,165,648 and over the last 5 years he sold TXG stock worth over $816,210. In addition, he makes $648,311 as Chief Financial Officer at 10x Genomics.
Sign up
Mr. McAnear TXG stock SEC Form 4 insiders trading
Justin has made over 39 trades of the 10x Genomics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,961 units of TXG stock worth $66,711 on 22 August 2024.
The largest trade he's ever made was exercising 19,841 units of 10x Genomics stock on 23 December 2020 worth over $99,999. On average, Justin trades about 6,185 units every 36 days since 2019. As of 22 August 2024 he still owns at least 143,242 units of 10x Genomics stock.
You can see the complete history of Mr. Anear stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Justin McAnear biography
Justin J. McAnear serves as Chief Financial Officer of the Company. Mr. Justin McAnear has served as our Chief Financial Officer since October 2018. From August 2015 to October 2018, Mr. McAnear was the Vice President of Worldwide Finance and Operations at Tesla. From September 2013 to August 2015, Mr. McAnear served as a Finance Director at Apple in Corporate FP&A and Worldwide Operations and from February 2011 to September 2013, Mr. McAnear served as a Senior Finance Manager in Worldwide Operations. Mr. McAnear began his corporate finance career at Johnson & Johnson in August 2006 and left in February 2011. Mr. McAnear served over nine years in the U.S. Navy as an aviator and is a graduate of the U.S. Naval Academy in Annapolis, MD, where he earned his B.S. degree in Systems Engineering. He also holds an M.B.A. in Finance from the University of San Diego.
What is the salary of Justin McAnear?
As the Chief Financial Officer of 10x Genomics, the total compensation of Justin McAnear at 10x Genomics is $648,311. There are 7 executives at 10x Genomics getting paid more, with Serge Saxonov having the highest compensation of $2,362,960.
How old is Justin McAnear?
Justin McAnear is 44, he's been the Chief Financial Officer of 10x Genomics since 2018. There are 12 older and 2 younger executives at 10x Genomics. The oldest executive at 10x Genomics, Inc. is John Stuelpnagel, 62, who is the Independent Chairman of the Board.
What's Justin McAnear's mailing address?
Justin's mailing address filed with the SEC is 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON, CA, 94588.
Insiders trading at 10x Genomics
Over the last 5 years, insiders at 10x Genomics have traded over $629,686,183 worth of 10x Genomics stock and bought 487,816 units worth $19,025,295 . The most active insiders traders include Bryan E Roberts, Capital Management I, Llc F... und Benjamin J. Hindson. On average, 10x Genomics executives and independent directors trade stock every 8 days with the average trade being worth of $1,002,346. The most recent stock trade was executed by Serge Saxonov on 22 August 2024, trading 6,749 units of TXG stock currently worth $152,055.
What does 10x Genomics do?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
What does 10x Genomics's logo look like?
Complete history of Mr. Anear stock trades at 10x Genomics
10x Genomics executives and stock owners
10x Genomics executives and other stock owners filed with the SEC include:
-
Serge Saxonov,
Chief Executive Officer, Co-Founder, Director -
Benjamin Hindson,
President, Co-Founder, Chief Scientific Officer, Director -
Sridhar Kosaraju,
Independent Director -
Shehnaaz Suliman,
Independent Director -
Eric Whitaker,
General Counsel -
Bryan Roberts,
Independent Director -
Dr. Serge Saxonov Ph.D.,
Co-Founder, CEO & Director -
Justin McAnear,
Chief Financial Officer -
Dr. Benjamin J. Hindson Ph.D.,
Co-Founder, Pres, Chief Scientific Officer & Director -
Bradford J. Crutchfield,
Chief Commercial Officer -
Ruth De Backer,
Chief Bus. Officer -
Justin J. McAnear,
Chief Financial Officer -
John Stuelpnagel,
Independent Chairman of the Board -
Mathai Mammen,
Independent Director -
Kimberly Popovits,
Independent Director -
Bradford Crutchfield,
Chief Commercial Officer -
Jean Philibert,
Chief People Officer -
Sam Ropp,
Sr. VP of Global Sales -
Jonathan Schimmel,
VP of Global Support & Sales Operations -
Eric S. Whitaker,
Gen. Counsel -
Cassie Corneau,
Mang. of Investor Relations and Strategic Fin. -
Paul W. Wyatt,
Sr. VP of Operations -
Capital Management, Llc Pal...,
-
Associates Vi, L.P.Venrock ...,
-
Vision Fund (Aiv M2) L.P.Sb...,
-
Capital Management I, Llc F...,
-
Sarah A. Teichmann,
-
James Wilbur,
Chief Commercial Officer -
Alan Mateo,